How to Get Jatenzo in Texas

What Jatenzo Is and Why Texas Patients Choose It

Jatenzo is the brand name for oral testosterone undecanoate (TU), approved by the FDA in March 2019 as the first oral testosterone replacement for adult men with hypogonadism caused by specific conditions. Unlike injectable testosterone cypionate or transdermal gels, Jatenzo is a twice-daily capsule taken with food. The lymphatic absorption pathway avoids hepatic first-pass metabolism, a design feature that separates it from older oral androgens like methyltestosterone, which carried significant liver toxicity risk.

The key registration trial by Swerdloff et al. (2020) enrolled 166 hypogonadal men and demonstrated that 87% of subjects on the 237 mg twice-daily dose achieved average serum testosterone in the eugonadal range (300 to 1 to 100 ng/dL) at day 90. The Endocrine Society's 2018 clinical practice guideline identifies testosterone replacement as appropriate for men with unequivocally low testosterone confirmed on at least two morning samples, combined with signs and symptoms of androgen deficiency. Jatenzo fits within that framework as an FDA-approved formulation option.

Texas is the second-largest state by population, with roughly 15 million adult men. The combination of large rural distances and limited endocrinology access makes telehealth-based TRT prescribing a practical pathway for many Texans who would otherwise face 100+ mile drives to a specialist.

Step-by-Step: Getting a Jatenzo Prescription in Texas

The process from initial consultation to capsules in hand follows a predictable sequence. A Texas-licensed prescriber must confirm the diagnosis before writing a Schedule III prescription.

1. Confirm eligibility with lab work. The Endocrine Society guideline requires two morning fasting total testosterone levels below 300 ng/dL, drawn between 7:00 and 10:00 AM. Most providers also order a complete metabolic panel, CBC, lipid panel, and PSA at baseline. A hematocrit above 50% is a relative contraindication per the AUA/Endocrine Society consensus, and PSA screening follows the AUA/ASCO 2023 guideline recommendations for men over 40.

2. Consult with a licensed prescriber. Texas Medical Board rules allow synchronous audio-video telehealth visits to establish a prescriber-patient relationship for controlled substances. In-person visits are not required for Schedule III drugs under Texas Occupations Code §111.005. Physicians (MD/DO), nurse practitioners with full prescriptive authority, and physician assistants under physician delegation can all prescribe Jatenzo in Texas.

3. Prescription routing. Once labs confirm hypogonadism and the prescriber selects Jatenzo, the prescription routes to a retail or specialty pharmacy. Because Jatenzo is a Schedule III controlled substance, electronic prescribing (EPCS) is required in Texas for most prescribers.

4. Pharmacy fills or ships. Most Texas retail chains (CVS, Walgreens, H-E-B Pharmacy) can order Jatenzo from wholesale distributors. Specialty pharmacies may stock it more reliably. Delivery timelines range from 2 to 7 business days for in-stock pharmacies, and up to 14 days if specialty ordering is needed.

Telehealth Prescribing Rules for Jatenzo in Texas

Texas fully permits telehealth prescribing of Schedule III controlled substances like testosterone undecanoate. The state does not require an initial in-person visit for this drug class.

The DEA's 2023 telemedicine prescribing flexibility extended pandemic-era rules allowing Schedule III to V substances via telemedicine without a prior in-person exam, provided the prescriber holds an active DEA registration. Texas mirrors this at the state level. A prescriber licensed by the Texas Medical Board or Texas Board of Nursing can conduct the entire evaluation, from reviewing labs to writing the Jatenzo prescription, through a synchronous video visit.

Patients should verify three things before booking a telehealth TRT consultation: the provider holds an active Texas medical license (searchable on the Texas Medical Board's verification portal), the provider has a DEA registration valid for Schedule III, and the platform complies with HIPAA. HealthRX meets all three requirements for Texas-based patients.

Lab Requirements Before and During Jatenzo Therapy

Baseline and follow-up labs are not optional. They protect patients from cardiovascular and hematologic risks and satisfy documentation requirements for insurance prior authorization.

Baseline labs (before first dose): The Endocrine Society guideline specifies two morning total testosterone draws, plus LH and FSH to distinguish primary from secondary hypogonadism. A CBC with hematocrit is required because testosterone stimulates erythropoiesis. In the Swerdloff et al. key trial, hematocrit exceeded 54% in 3.6% of subjects on the 237 mg dose, a rate comparable to other testosterone formulations. A lipid panel is recommended since oral TU can decrease HDL cholesterol. In the registration study, mean HDL dropped by approximately 4 mg/dL from baseline at 120 days. Hepatic function tests (AST, ALT) round out the panel, though Jatenzo's lymphatic absorption largely bypasses the liver.

Follow-up labs: Repeat total testosterone, CBC, and hepatic panel at 3 months, 6 months, and then annually. The 2018 Endocrine Society guideline recommends checking hematocrit at 3 to 6 months and annually thereafter. If hematocrit exceeds 54%, the guideline advises dose reduction, therapeutic phlebotomy, or discontinuation. A PSA check at 3 to 6 months and at 12 months is standard for men over 40. A PSA rise exceeding 1.4 ng/mL within 12 months warrants urologic evaluation per the AUA guideline.

The FDA label also carries a boxed warning for blood pressure increases. In the registration trial, systolic BP increased by a mean of 3 to 5 mmHg. Home BP monitoring is a practical addition to lab surveillance, especially for patients with pre-existing hypertension.

Insurance Coverage and Prior Authorization in Texas

Coverage for brand-name Jatenzo varies widely across Texas insurers. Expect friction. This is a high-cost branded oral formulation competing against generic injectables that cost under $40 per month.

Texas Medicaid: Does not cover Jatenzo for standard male hypogonadism. The Texas Medicaid formulary restricts oral testosterone undecanoate to narrow indications related to type 2 diabetes. Patients on Medicaid would need to pay cash or switch to a covered formulation.

Commercial insurance: Most commercial plans in Texas classify Jatenzo as non-preferred or Tier 3. Prior authorization is nearly universal. To file a successful PA, providers should submit:

• Two documented morning total testosterone values below 300 ng/dL (with lab timestamps)
• A diagnosis code for male hypogonadism (E29.1 for primary, E23.0 for secondary)
• Clinical rationale for oral over injectable (needle phobia, injection-site reactions, patient preference documented in chart)
• Failure of or contraindication to at least one generic testosterone formulation (most plans require step therapy)

The American Association of Clinical Endocrinology (AACE) 2024 clinical practice statement supports oral testosterone undecanoate as a valid formulation choice, which can strengthen appeal letters when initial PA is denied.

Cash price: Without insurance, Jatenzo runs approximately $500 to $700 per month at Texas retail pharmacies. Tolmar's manufacturer savings program may reduce copays to as low as $0 for commercially insured patients, though uninsured patients typically cannot access manufacturer coupons. GoodRx and similar platforms occasionally list prices near $450 at specific Texas locations.

503A Compounding Pharmacies and Oral Testosterone in Texas

Texas-licensed 503A compounding pharmacies can compound oral testosterone undecanoate capsules for individual patients with a valid prescription. This is a distinct product from brand Jatenzo.

The Texas State Board of Pharmacy regulates 503A pharmacies under state and federal law. A 503A pharmacy compounds patient-specific prescriptions, not bulk manufacturing. The FDA's guidance on 503A compounding requires that the compounded drug is not a copy of an FDA-approved product if that product is commercially available. Because Jatenzo is commercially available, some regulatory gray area exists around compounding "copies." In practice, many 503A pharmacies compound testosterone undecanoate capsules at different strengths or with different excipients, creating a distinct formulation.

Compounded oral TU capsules typically cost $150 to $300 per month, a meaningful savings over brand Jatenzo. Patients should confirm that their compounding pharmacy holds a current Texas State Board of Pharmacy license, uses USP-grade testosterone undecanoate powder, and provides third-party potency testing. The FDA has issued multiple warnings about substandard compounding practices, and potency verification protects against under- or over-dosing.

Jatenzo Dosing, Timing, and Food Requirements

The starting dose is 237 mg taken twice daily with food. The food requirement is not a suggestion. Without a fat-containing meal, absorption drops by approximately 50%, based on pharmacokinetic data from the FDA label.

Each capsule should be swallowed whole. Do not chew or open them. The Swerdloff et al. trial used meals containing at least 30% fat calories to standardize absorption. In clinical practice, a breakfast with eggs and avocado or a dinner with olive oil provides sufficient fat content.

Dose adjustments follow a simple algorithm from the FDA label: if the average serum testosterone at follow-up is below 300 ng/dL, increase to 396 mg twice daily. If it exceeds 1 to 100 ng/dL, decrease to 158 mg twice daily. If testosterone remains above 1 to 100 ng/dL on 158 mg twice daily, discontinue the drug.

The twice-daily oral schedule is Jatenzo's most common adherence barrier. Missed doses should be taken at the next scheduled time. Do not double up. Patients who consistently miss the evening dose may see subtherapeutic trough levels by the next morning.

Cardiovascular Safety Considerations

The FDA issued a class-wide safety communication in 2015 requiring all testosterone products to carry warnings about possible increased cardiovascular risk. Jatenzo's label includes this warning alongside product-specific data on blood pressure elevation.

The TRAVERSE trial (Lincoff et al., NEJM 2023; N=5,246) was the first large, randomized, placebo-controlled cardiovascular outcomes trial for testosterone. While TRAVERSE studied transdermal testosterone gel rather than oral TU specifically, it found no significant increase in major adverse cardiovascular events (HR 0.99 to 95% CI 0.81 to 1.21) over a median 33 months. This provides a degree of cardiovascular reassurance for the testosterone class, though direct extrapolation to oral TU requires caution given Jatenzo's distinct pharmacokinetic profile and its effect on HDL cholesterol reduction.

A 2018 meta-analysis in Expert Opinion on Drug Safety reviewing testosterone formulations found that hematocrit elevation and HDL reduction were the most consistent adverse signals across formulations. Monitoring both remains the clinical priority.

Who Should Not Take Jatenzo

Per the FDA prescribing information, Jatenzo is contraindicated in men with breast cancer, known or suspected prostate cancer, women who are or may become pregnant, and individuals with serious cardiac, hepatic, or renal disease. It is also contraindicated in men with a hematocrit above 55% at baseline. The Endocrine Society guideline adds untreated severe obstructive sleep apnea, uncontrolled heart failure, and a desire for near-term fertility as relative contraindications, since exogenous testosterone suppresses spermatogenesis through hypothalamic-pituitary-gonadal axis suppression.

Transferring an Existing Jatenzo Prescription to Texas

Patients relocating to Texas with an active Jatenzo prescription can transfer it to a Texas pharmacy if the prescriber holds an active license recognized by Texas. For out-of-state prescriptions, most Texas pharmacies will accept a Schedule III transfer if the originating pharmacy confirms the prescription's validity. Texas requires that controlled substance prescriptions be transferred only once, per Texas Administrative Code §291.34. If the patient's prescriber is not Texas-licensed, a new Texas-licensed provider must write a fresh prescription after reviewing records and current labs.